Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Increased by Creative Planning

Creative Planning lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,615 shares of the biopharmaceutical company’s stock after purchasing an additional 991 shares during the quarter. Creative Planning’s holdings in Regeneron Pharmaceuticals were worth $10,106,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Copperwynd Financial LLC lifted its position in Regeneron Pharmaceuticals by 4.6% in the second quarter. Copperwynd Financial LLC now owns 788 shares of the biopharmaceutical company’s stock worth $851,000 after purchasing an additional 35 shares during the period. Aviso Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 28.1% in the 2nd quarter. Aviso Wealth Management now owns 1,645 shares of the biopharmaceutical company’s stock worth $1,729,000 after buying an additional 361 shares in the last quarter. Susquehanna Fundamental Investments LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 1,719.2% in the second quarter. Susquehanna Fundamental Investments LLC now owns 23,286 shares of the biopharmaceutical company’s stock valued at $24,474,000 after buying an additional 22,006 shares during the period. Lighthouse Investment Partners LLC boosted its stake in Regeneron Pharmaceuticals by 141.6% during the second quarter. Lighthouse Investment Partners LLC now owns 12,536 shares of the biopharmaceutical company’s stock valued at $13,176,000 after buying an additional 7,348 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in Regeneron Pharmaceuticals by 3.7% during the second quarter. Mackenzie Financial Corp now owns 57,964 shares of the biopharmaceutical company’s stock worth $60,922,000 after acquiring an additional 2,074 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on REGN shares. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Truist Financial reissued a “buy” rating and set a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Piper Sandler boosted their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,118.62.

Insider Transactions at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,033 shares of company stock worth $9,399,345. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Down 0.4 %

REGN stock opened at $1,046.91 on Wednesday. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The firm has a market cap of $115.41 billion, a PE ratio of 30.93, a PEG ratio of 3.56 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The company has a fifty day simple moving average of $1,128.37 and a 200 day simple moving average of $1,036.74.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the prior year, the firm posted $8.79 EPS. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.